Zurich Cantonal Bank
LRMR icon

Zurich Cantonal Bank’s Larimar Therapeutics LRMR Stock Holding History

Zurich Cantonal Bank’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,395
Closed -$26K – 2790
2021
Q4 		$26K Sell
2,395
-249
-9% -$2.77K ﹤0.01% 2839
2021
Q3 		$30K Buy
2,644
+9
+0.3% +$108 ﹤0.01% 2740
2021
Q2 		$26K Buy
2,635
+273
+12% +$3.08K ﹤0.01% 2560
2021
Q1 		$35K Buy
+2,362
New +$42.9K ﹤0.01% 2479

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Zurich Cantonal Bank's LRMR Position: Q1 2022 in Review

Zurich Cantonal Bank sold out of Larimar Therapeutics (LRMR) in Q1 2022, closing a stake of 2,395 shares — an estimated $26K sold.

Zurich Cantonal Bank first reported a position in LRMR in Q1 2021 and held it in 4 quarters. The position peaked at $35K in Q1 2021. 45 funds tracked by Wall St. Rank hold LRMR as of Q1 2022.

  • Zurich Cantonal Bank reported no remaining Larimar Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Zurich Cantonal Bank sold 2,395 Larimar Therapeutics shares in Q1 2022, an estimated $26K.
  • Zurich Cantonal Bank first reported a position in Larimar Therapeutics in Q1 2021 and held it in 4 quarters.
  • Zurich Cantonal Bank's Larimar Therapeutics position peaked at $35K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2022.

Based on Zurich Cantonal Bank's 13F filing for Q1 2022, filed 21 Apr 2022.